Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitor”

2,878 pharma patents match "inhibitor" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,878
Index total 30,257
Page 7 / 120

Quick answer

This filtered view shows 2,878 pharmaceutical patents matching "inhibitor" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,878 results for “inhibitor” · 30,257 patents in full index Clear search

  1. US 12172994

    Pyrimidine compound as JAK kinase inhibitor

    Theravance Biopharma R&D IP, LLC · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  2. US 12171760

    Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors

    Corcept Therapeutics Incorporated · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  3. US 12171765

    Combination therapies using PRMT5 inhibitors for the treatment of cancer

    Mirati Therapeutics, Inc. · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  4. US 12168023

    Inhibitors of adenosine 5′-nucleotidase

    Arcus Biosciences, Inc. · Granted Dec 17, 2024 · Expires Dec 12, 2044

    granted
  5. US 12162877

    Human dihydroorotate dehydrogenase (hDHODH) inhibitors and their use in targeting oncological diseases sensitive to pyrimidine starvation

    DRUG DISCOVERY AND CLINIC S.R.L. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  6. US 12162838

    Human plasma kallikrein inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  7. US 12161618

    Methods of identifying and treating patients with HIF-2 inhibitor resistance

    The Board of Regents of the University of Texas System · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  8. US 12162818

    Inhibitors of the n-terminal domain of the androgen receptor

    The United States Government represented by the Department of Veterans Affairs · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  9. US 12157891

    Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 3, 2024 · Expires Nov 28, 2044

    granted
  10. US 12156879

    Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy

    UNIVERSITY OF CONNECTICUT · Granted Dec 3, 2024 · Expires Nov 28, 2044

    granted
  11. US 12156880

    Heterocyclic RIP1 kinase inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Dec 3, 2024 · Expires Nov 28, 2044

    granted
  12. US 2024390332

    Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Nov 28, 2024 · Expires Nov 23, 2044

    granted
  13. US 2024390317

    COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Nov 28, 2024 · Expires Nov 23, 2044

    granted
  14. US 12152034

    FGFR inhibitors and methods of making and using the same

    Relay Therapeutics, Inc. · Granted Nov 26, 2024 · Expires Nov 21, 2044

    granted
  15. US 12145925

    Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer

    The Regents of the University of California · Granted Nov 19, 2024 · Expires Nov 14, 2044

    granted
  16. US 12144813

    PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

    Cardiff Oncology, Inc. · Granted Nov 19, 2024 · Expires Nov 14, 2044

    granted
  17. US 12145944

    Imidazopyrimidines as EED inhibitors and the use thereof

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Nov 19, 2024 · Expires Nov 14, 2044

    granted
  18. US 12138263

    Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof

    Relay Therapeutics, Inc. · Granted Nov 12, 2024 · Expires Nov 7, 2044

    granted
  19. US 12133849

    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeutic

    Actinium Phamaceuticals, Inc. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  20. US 12128015

    APE/REF1 inhibitors for the treatment of cancer

    The Regents of the University of California · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  21. US 12129262

    CDK inhibitors and their use as pharmaceuticals

    Prelude Therapeutics, Incorporated · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  22. US 12128048

    Combination therapies using PRMT5 inhibitors for the treatment of cancer

    Mirati Therapeutics, Inc. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  23. US 12129263

    Kinase inhibitors and uses thereof

    DENALI THERAPEUTICS INC. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  24. US 12122773

    Crystalline hydrate of a JAK inhibitor compound

    Theravance Biopharma R&D IP, LLC · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted